Higher sRAGE Levels Predict Mortality in Frail Older Adults with Cardiovascular Disease.

Autor:	Butcher L; The Cellular Senescence and Pathophysiology Group, Cardiff Metropolitan University, Cardiff, United Kingdom., Carnicero JA; Fundación Para La Investigación Biomédica Del Hospital Universitario De Getafe, Getafe, Spain., Pérès K; Inserm, Bordeaux Population Health Research Center, Bordeaux, France., Colpo M; Department of Statistics, University of Florence, Florence, Italy., Gomez Cabrero D; Unit of Computational Medicine, Karolinska Institute, Stockholm, Sweden., Dartigues JF; Inserm, Bordeaux Population Health Research Center, Bordeaux, France., Bandinelli S; Geriatric Unit, Local Health Tuscany Center Agency, Florence, Italy., Garcia-Garcia FJ; Division of Geriatric Medicine, Hospital Virgen del Valle, Complejo Hospitalario de Toledo, Toledo, Spain., Rodríguez-Mañas L; Fundación Para La Investigación Biomédica Del Hospital Universitario De Getafe, Getafe, Spain., Erusalimsky JD; The Cellular Senescence and Pathophysiology Group, Cardiff Metropolitan University, Cardiff, United Kingdom, jderusalimsky@cardiffmet.ac.uk.
Jazyk:	angličtina
Zdroj:	Gerontology [Gerontology] 2021; Vol. 67 (2), pp. 202-210. Date of Electronic Publication: 2021 Jan 21.
DOI:	10.1159/000512287
Abstrakt:	Introduction: The evidence that blood levels of the soluble receptor for advanced glycation end products (sRAGE) predict mortality in people with cardiovascular diseases (CVD) is inconsistent. To clarify this matter, we investigated if frailty status influences this association. Methods: We analysed data of 1,016 individuals (median age, 75 years) from 3 population-based European cohorts, enrolled in the FRAILOMIC project. Participants were stratified by history of CVD and frailty status. Mortality was recorded during 8 years of follow-up. Results: In adjusted Cox regression models, baseline serum sRAGE was positively associated with an increased risk of mortality in participants with CVD (HR 1.64, 95% CI 1.09-2.49, p = 0.019) but not in non-CVD. Within the CVD group, the risk of death was markedly enhanced in the frail subgroup (CVD-F, HR 1.97, 95% CI 1.18-3.29, p = 0.009), compared to the non-frail subgroup (CVD-NF, HR 1.50, 95% CI 0.71-3.15, p = 0.287). Kaplan-Meier analysis showed that the median survival time of CVD-F with high sRAGE (>1,554 pg/mL) was 2.9 years shorter than that of CVD-F with low sRAGE, whereas no survival difference was seen for CVD-NF. Area under the ROC curve analysis demonstrated that for CVD-F, addition of sRAGE to the prediction model increased its prognostic value. Conclusions: Frailty status influences the relationship between sRAGE and mortality in older adults with CVD. sRAGE could be used as a prognostic marker of mortality for these individuals, particularly if they are also frail. (© 2021 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu